Common Contracts
13 similar Severance & Change in Control Agreement contracts by Arcutis Biotherapeutics, Inc.
equal to the monthly premiums that would have been paid on behalf of Executive had such payments commenced on the date of the Qualifying Termination. Notwithstanding the foregoing, the Company may elect that, in lieu of paying or reimbursing the...Severance & Change in Control Agreement • April 10th, 2024 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENT This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between L. Todd Edwards (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware...Severance & Change in Control Agreement • September 27th, 2023 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
Arcutis Biotherapeutics, Inc. Severance & Change in Control AgreementSeverance & Change in Control Agreement • February 22nd, 2022 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Masaru Matsuda (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), and is effective as of the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • May 6th, 2021 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Scott L. Burrows (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), and is effective as of the date that this Agreement is signed by both parties (the “Effective Date”). This Agreement supersedes the Severance & Change in Control Agreement previously entered into by and between the Executive and the Company which was effective as of the first date on which the registration statement on Form S-1 for the initial public offering of the Company’s Common Stock was declared effective by the United States Securities and Exchange Commission or, if later, the date that the prior agreement was signed.
Arcutis Biotherapeutics, Inc. Severance & Change in Control AgreementSeverance & Change in Control Agreement • February 16th, 2021 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Matthew R. Moore (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the date that Executive commences employment with the Company (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • July 29th, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Patrick Burnett (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Kenneth A. Lock (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between John W. Smither (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Todd Franklin Watanabe (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Patricia A. Turney (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between David W. Osborne (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Howard G. Welgus (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTSeverance & Change in Control Agreement • January 6th, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between ________________ (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
